NEKTAR THERAPEUTICS - NKTR
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND L P | 5.3% | 1,523,980 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF I GP LLC | 5.3% | 1,523,980 | View |
| May 15, 2026 | SCHEDULE 13G/A | BIOTECHNOLOGY VALUE FUND II LP | 3.9% | 1,114,072 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF II GP LLC | 3.9% | 1,114,072 | View |
| May 15, 2026 | SCHEDULE 13G/A | Biotechnology Value Trading Fund OS LP | 0.6% | 171,769 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF Partners OS Ltd. | 0.6% | 171,769 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF GP HOLDINGS LLC | 9.1% | 2,638,052 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF PARTNERS L P/IL | 9.8% | 2,852,698 | View |
| May 15, 2026 | SCHEDULE 13G/A | BVF INC/IL | 9.8% | 2,852,698 | View |
| May 15, 2026 | SCHEDULE 13G/A | LAMPERT MARK N | 9.8% | 2,852,698 | View |
| May 06, 2026 | SCHEDULE 13G/A | FMR LLC | 15.0% | 4,303,188 | View |
| May 06, 2026 | SCHEDULE 13G/A | Abigail P. Johnson | 15.0% | 4,303,188 | View |
| Apr 17, 2026 | SCHEDULE 13G | Two Seas Capital LP | 6.8% | 1,959,178 | View |
| Apr 17, 2026 | SCHEDULE 13G | Two Seas Capital GP LLC | 6.8% | 1,959,178 | View |
| Apr 17, 2026 | SCHEDULE 13G | Sina Toussi | 6.8% | 1,959,178 | View |
| Mar 27, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Mar 06, 2026 | SCHEDULE 13G | FMR LLC | 11.1% | 3,036,761 | View |
| Mar 06, 2026 | SCHEDULE 13G | Abigail P. Johnson | 11.1% | 3,036,761 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | G1 Execution Services, LLC | 4.0% | 809,967 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Susquehanna Portfolio Strategies, LLC | 4.0% | 809,967 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Susquehanna Securities, LLC | 4.0% | 809,967 | View |
| Jan 30, 2026 | SCHEDULE 13G | The Vanguard Group | 5.04% | 1,027,089 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.